CliffBio
small molecule

BROMFENAC SODIUM

BROMFENAC SODIUM

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBROMFENAC SODIUM
Active ingredientBROMFENAC SODIUM
StrengthEQ 0.07% ACID
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.